Immunotherapy for Ovarian Cancer: 12 Real Stories

12 stories match ovarian cancer and immunotherapy. 11 of them mention chemotherapy.

Cancer Stories

Caitlin, who was diagnosed with Stage II Ovarian Squamous Cell CarcinomaOvarian Cancer

Stage II Ovarian Squamous Cell Carcinoma: Caitlin's Survivor Story

Patient Info: Caitlin Koehler, female, Under 40 | Stage II

Biomarkers: PD-L1: high expression

After surgery for recurrence, Caitlin remained on maintenance therapy and her follow-up scans showed no evidence of disease.

MD Anderson
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Durable response after multiple treatments for ovarian clear cell cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HRD-positive; BRCA-negative; ARID1A mutation; PD-L1 CPS 30

She achieved a complete response, completed maintenance immunotherapy in May 2024, and continued anlotinib with normal follow-up imaging and tumor markers.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage III Small Cell Lung CancerOvarian Cancer

Small Cell Ovarian Cancer Causing Acute Kidney Injury

Patient Info: Anonymized, Female | Stage III

Biomarkers: Somatic SMARCA4 alterations; no germline SMARCA4 pathogenic variant

Combined pembrolizumab, carboplatin, and paclitaxel was continued after marked radiologic improvement, with an excellent PET-CT response documented after 13 cycles.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Ovarian CancerOvarian Cancer

Ovarian Cancer Spreads to the Breast During Platinum-Resistant Recurrence

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: BRCA1/2-negative; HRD-positive; PD-L1-positive; folate receptor alpha-positive

Metastatic Site: right breast, right axillary lymph nodes, cervical…

She remained alive with stable disease about 2 years after the breast metastasis was diagnosed while receiving seventh-line mirvetuximab-soravtansine.

PubMed Central
OutcomeStable Disease
Susan, who was diagnosed with Stage IV Ovarian CancerOvarian Cancer

Stage IV Ovarian Cancer: Susan's Patient Story

Patient Info: Susan Dunwoody, female | Stage IV

Susan lived for 7 years after her Stage IV ovarian cancer diagnosis and later died from the disease.

MD Anderson
OutcomeIn Memory
Jaclyn, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Jaclyn's Patient Story

Patient Info: Jaclyn (Jackie) VanRaaphorst | Stage III

Biomarkers: FRα-positive; CA-125 monitored

AACR later reported that Jackie died on January 16, 2025.

AACR
OutcomeIn Memory
Elle, who was diagnosed with Stage I Ovarian CancerOvarian Cancer

Stage I Ovarian Cancer: Elle's Patient Story

Patient Info: Elle Simone Scott, Female, Under 40 | Stage I

Living with recurrent ovarian cancer for more than 6 years after her September 2016 diagnosis, with an active clinical trial slowing progression at the May 2023 publication.

Dana-Farber
OutcomeLiving With Cancer
Karoline, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Karoline's Patient Story

Patient Info: Karoline Strauss, female | Stage III

After resuming etigilimab and nivolumab, the patient felt markedly better; by the eighth infusion, some tumors had disappeared and others were shrinking, and treatment was continuing.

MD Anderson
OutcomeResponding Well
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

Metastatic Clear Cell Ovarian Cancer Complicated by Treatment-Related Sarcoidosis

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Metastatic Site: peritoneum

During a treatment holiday, biopsy and laboratory evaluation showed treatment-related sarcoidosis rather than ovarian-cancer spread in the enlarged lymph nodes. After prednisone, the sarcoidosis resolved and imaging showed no progression of the clear cell ovarian cancer; she remained clinically well 4 months later.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Ovarian CancerOvarian Cancer

MSI-High Malignant Struma Ovarii With Lung and Liver Metastases 17 Years Later

Patient Info: Anonymized, Female, 50s | Stage Metastatic/Advanced

Biomarkers: NRAS, and ATM mutations; Ki-67 approximately 15%–29%

Metastatic Site: lungs|liver

She remained asymptomatic and tolerated pembrolizumab without obvious adverse effects after 4 doses, with follow-up imaging planned for metastatic lung and liver disease.

PubMed Central
OutcomeCare Ongoing
Jackie, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Jackie's Survivor Story

Patient Info: Jackie Page, Female, 50s | Stage III

In remission with no sign of recurrent disease at the September 2020 publication, while continuing treatment on the clinical trial.

Dana-Farber
OutcomeCancer-Free / NED
Dianne, who was diagnosed with Stage III Ovarian CancerOvarian Cancer

Stage III Ovarian Cancer: Dianne's Patient Story

Patient Info: Dianne Simpson, female, 70+ | Stage III

Dianne completed treatment in April 2017 after chemotherapy, hysterectomy and a pembrolizumab clinical trial and was looking ahead to survivorship.

MD Anderson
OutcomeNot reported